Biocept Liquid Biopsy ROS1 Assay

Biocept announced it has launched a blood-based ROS1 rearrangement test for non-small cell lung cancer patients. The assay, which will be performed at the firm's CLIA-certified and CAP-accredited laboratory, detects ROS1 rearrangements in circulating tumor cells in order to determine if NSCLC patients might benefit from molecularly targeted drugs.